With plans to spend $360M, As­traZeneca will build its first-ever man­u­fac­tur­ing site in Ire­land

As­traZeneca is plan­ning to spend a pret­ty pen­ny for a new man­u­fac­tur­ing fa­cil­i­ty in Dublin.

The Big Phar­ma will shell out $360 mil­lion to build an API plant for small mol­e­cules at its Alex­ion cam­pus in Col­lege Park, Dublin, it an­nounced Tues­day morn­ing. As­traZeneca said the fo­cus of the fa­cil­i­ty will be late-stage de­vel­op­ment and ear­ly com­mer­cial sup­ply for small mol­e­cule ther­a­pies.

“The fu­ture man­u­fac­tur­ing of APIs for our med­i­cines in­cludes com­pounds with high­ly com­plex syn­the­sis, re­quir­ing next gen­er­a­tion tech­nolo­gies and ca­pa­bil­i­ties that can re­spond quick­ly and nim­bly to rapid­ly-chang­ing clin­i­cal and com­mer­cial needs,” As­traZeneca glob­al ops chief Pam Cheng said in a state­ment. “This sig­nif­i­cant in­vest­ment will en­sure the As­traZeneca sup­ply net­work is fit for the fu­ture.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER